|
1
|
Marx RE: Pamidronate (Aredia) and
zoledronate (Zometa) induced avascular necrosis of the jaws: A
growing epidemic. J Oral Maxillofac Surg. 61:1115–1117. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marx RE, Sawatari Y, Fortin M and Broumand
V: Bisphosphonate-induced exposed bone
(osteonecrosis/osteopetrosis) of the jaws: Risk factors,
recognition, prevention, and treatment. J Oral Maxillofac Surg.
63:1567–1575. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pires FR, Miranda A, Cardoso ES, Cardoso
AS, Fregnani ER, Pereira CM, Correa ME, Almeida JP, Alves Fde A,
Lopes MA and de Almeida OP: Oral avascular bone necrosis associated
with chemotherapy and biphosphonate therapy. Oral Dis. 11:365–369.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma D, Ivanovski S, Slevin M, Hamlet S,
Pop TS, Brinzaniuc K, Petcu EB and Miroiu RI:
Bisphosphonate-related osteonecrosis of jaw (BRONJ): Diagnostic
criteria and possible pathogenic mechanisms of an unexpected
anti-angiogenic side effect. Vasc Cell. 5:12013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Petcu EB, Ivanovski S, Wright RG, Slevin
M, Miroiu RI and Brinzaniuc K: Bisphosphonate-related osteonecrosis
of jaw (BRONJ): An anti-angiogenic side-effect? Diagn Pathol.
7:782012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Otrock ZK, Mahfouz RAR, Makarem JA and
Shamseddine AI: Understanding the biology of angiogenesis: Review
of the most important molecular mechanisms. Blood Cells Mol Dis.
39:212–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wood J, Bonjean K, Ruetz S, Bellahcene A,
Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic
effects of the bisphosphonate compound zoledronic acid. J Pharmacol
Exp Ther. 302:1055–1061. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamada J, Tsuno NH, Kitayama J, Tsuchiya
T, Yoneyama S, Asakage M, Okaji Y, Shuno Y, Nishikawa T, Tanaka J,
et al: Anti-angiogenic property of zoledronic acid by inhibition of
endothelial progenitor cell differentiation. J Surg Res.
151:115–120. 2009. View Article : Google Scholar
|
|
9
|
Brass AL, Huang IC, Benita Y, John SP,
Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig
E, et al: The IFITM proteins mediate cellular resistance to
influenza A H1N1 virus, West Nile virus, and dengue virus. Cell.
139:1243–1254. 2009. View Article : Google Scholar
|
|
10
|
Hatano H, Kudo Y, Ogawa I, Tsunematsu T,
Kikuchi A, Abiko Y and Takata T: IFN-induced transmembrane protein
1 promotes invasion at early stage of head and neck cancer
progression. Clin Cancer Res. 14:6097–6105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu F, Ng SS, Chow BK, Sze J, Lu G, Poon
WS, Kung HF and Lin MC: Knockdown of interferon-induced
transmembrane protein 1 (IFITM1) inhibits proliferation, migration,
and invasion of glioma cells. J Neurooncol. 103:187–195. 2011.
View Article : Google Scholar
|
|
12
|
Pan Z, Chen S, Pan X, Wang Z, Han H, Zheng
W, Wang X, Li F, Qu S and Shao R: Differential gene expression
identified in uigur women cervical squamous cell carcinoma by
suppression subtractive hybridization. Neoplasma. 57:123–128. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Popson SA, Ziegler ME, Chen X, Holderfield
MT, Shaaban CI, Fong AH, Welch-Reardon KM, Papkoff J and Hughes CC:
Interferon-induced transmembrane protein 1 regulates endothelial
lumen formation during angiogenesis. Arterioscler Thromb Vasc Biol.
34:1011–1019. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vescovi P, Merigo E, Meleti M, Manfredi M,
Guidotti R and Nammour S: Bisphosphonates-related osteonecrosis of
the jaws: A concise review of the literature and a report of a
single-centre experience with 151 patients. J Oral Pathol Med.
41:214–221. 2012. View Article : Google Scholar
|
|
16
|
Bagan JV, Murillo J, Jimenez Y, Poveda R,
Milian MA, Sanchis JM, Silvestre FJ and Scully C: Avascular jaw
osteonecrosis in association with cancer chemotherapy: Series of 10
cases. J Oral Pathol Med. 34:120–123. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Misso G, Porru M, Stoppacciaro A,
Castellano M, De Cicco F, Leonetti C, Santini D and Caraglia M:
Evaluation of the in vitro and in vivo antiangiogenic effects of
denosumab and zoledronic acid. Cancer Biol Ther. 13:1491–1500.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ponce ML: Tube formation: An in vitro
matrigel angiogenesis assay. Methods Mol Biol. 467:183–188. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Michailidou M, Brown HK, Lefley DV, Evans
A, Cross SS, Coleman RE, Brown NJ and Holen I: Microvascular
endothelial cell responses in vitro and in vivo: Modulation by
zoledronic acid and paclitaxel? J Vasc Res. 47:481–493. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fournier P, Boissier S, Filleur S,
Guglielmi J, Cabon F, Colombel M and Clezardin P: Bisphosphonates
inhibit angiogenesis in vitro and testosterone-stimulated vascular
regrowth in the ventral prostate in castrated rats. Cancer Res.
62:6538–6544. 2002.PubMed/NCBI
|
|
21
|
Coxon JP, Oades GM, Kirby RS and Colston
KW: Zoledronic acid induces apoptosis and inhibits adhesion to
mineralized matrix in prostate cancer cells via inhibition of
protein prenylation. BJU Int. 94:164–170. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsai SH, Huang PH, Chang WC, Tsai HY, Lin
CP, Leu HB, Wu TC, Chen JW and Lin SJ: Zoledronate inhibits
ischemia-induced neovascularization by impairing the mobilization
and function of endothelial progenitor cells. PLoS One.
7:e410652012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Di Salvatore M, Orlandi A, Bagala C,
Quirino M, Cassano A, Astone A and Barone C: Anti-tumour and
anti-angiogenetic effects of zoledronic acid on human
non-small-cell lung cancer cell line. Cell Prolif. 44:139–146.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li S and De Souza P: Ras Isoprenylation
and pAkt Inhibition by zoledronic acid and fluvastatin enhances
paclitaxel activity in T24 bladder cancer cells. Cancers (Basel).
3:662–674. 2011. View Article : Google Scholar
|
|
25
|
Jaffe EA, Armellino D, Lam G, Cordon-Cardo
C, Murray HW and Evans RL: IFN-gamma and IFN-alpha induce the
expression and synthesis of Leu 13 antigen by cultured human
endothelial cells. J Immunol. 143:3961–3966. 1989.PubMed/NCBI
|
|
26
|
Yu F, Ng SSM, Chow BKC, Sze J, Lu G, Poon
WS, Kung HF and Lin MCM: Knockdown of interferon-induced
transmembrane protein 1 (IFITM1) inhibits proliferation, migration,
and invasion of glioma cells. J Neurooncol. 103:187–195. 2011.
View Article : Google Scholar
|
|
27
|
Tanaka SS, Yamaguchi YL, Tsoi B, Lickert H
and Tam PP: IFITM/Mil/fragilis family proteins IFITM1 and IFITM3
play distinct roles in mouse primordial germ cell homing and
repulsion. Dev Cell. 9:745–756. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bergers G, Brekken R, McMahon G, Vu TH,
Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z and
Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic
switch during carcinogenesis. Nature Cell Biol. 2:737–744. 2000.
View Article : Google Scholar : PubMed/NCBI
|
